EMERGENT BIOSOLUTIONS ($NYSE:EBS) reported total revenue of USD 337.9 million for the second quarter of FY2023, showing an increase of 39.2% from the same period in the previous year. However, net income decreased to USD -261.3 million from -56.4 million in Q2 of FY2022.
On Tuesday, EMERGENT BIOSOLUTIONS reported strong financial results for the second quarter of the fiscal year 2023. The company’s stock opened at $7.4 and closed at $7.2, down by 2.7% from the last closing price of 7.4. Despite the dip, the company’s overall performance indicated promising growth in the near future. Furthermore, the company was able to expand its portfolio of products with the launch of several new products over the past quarter. This includes a new diagnostic system that uses a combination of bioinformatics and machine learning to identify pathogens and diagnose diseases.
Additionally, EMERGENT BIOSOLUTIONS is expanding its presence in the development of vaccines and treatments for rare diseases. The company is well positioned to continue its growth trajectory in the coming quarters. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Emergent Biosolutions. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Emergent Biosolutions. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Emergent Biosolutions. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Emergent Biosolutions are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
GoodWhale recently conducted an analysis of EMERGENT BIOSOLUTIONS‘s wellbeing. We used the Star Chart to evaluate their performance in four categories: profitability, asset, dividend, and growth. Based on our findings, EMERGENT BIOSOLUTIONS is strong in profitability, medium in asset and weak in dividend and growth. We classified EMERGENT BIOSOLUTIONS as an ‘elephant’, a type of company that is typically rich in assets after deducting off liabilities. We believe that value investors, growth investors, and dividend investors may be interested in investing in such a company. When considering the health score of EMERGENT BIOSOLUTIONS, we found that they have an intermediate score of 5/10. This indicates that they have a good cashflow and debt ratio and should be able to safely ride out any crisis without the risk of bankruptcy. More…
Risk Rating Analysis
Star Chart Analysis
The competition in the global market for biopharmaceuticals is intense. The leading companies are all vying for market share with innovative products and cutting-edge research and development. Emergent BioSolutions Inc is one of the leading companies in this industry, and its main competitors are Phoenix Life Sciences International Ltd, Swedencare AB, Avivagen Inc.
– Phoenix Life Sciences International Ltd ($OTCPK:PLSI)
At 365.91k, Phoenix Life Sciences International Ltd has a market cap that is significantly lower than many of its competitors. However, its Return on Equity of -23.05% is much higher than many of its peers. This indicates that the company is doing a better job of generating profits for its shareholders.
Phoenix Life Sciences International Ltd is a pharmaceutical company that focuses on the development and commercialization of innovative drugs and therapies. The company has a strong portfolio of products in various stages of development, including several that are already on the market. Phoenix Life Sciences International Ltd is a relatively small company, but it has a strong potential for growth.
Swedencare AB is a pharmaceutical company that focuses on developing and commercializing products for the treatment of animals. The company has a market cap of 574.34M as of 2022 and a ROE of 0.81%. Swedencare’s products are available in over 50 countries and are used by veterinarians and pet owners alike. The company’s mission is to improve the quality of life for animals by providing innovative and effective solutions to common health problems.
Avivagen Inc is a Canadian biotechnology company that is engaged in the research, development and commercialization of natural products for the animal health industry. The company’s products are based on its proprietary technology, which leverages the natural properties of oxygen to kill bacteria and viruses. Avivagen’s products are designed to improve the health and productivity of livestock animals, companion animals and fish.
Avivagen Inc has a market cap of 10.42M as of 2022, a Return on Equity of 64.42%. The company’s products are based on its proprietary technology, which leverages the natural properties of oxygen to kill bacteria and viruses. Avivagen’s products are designed to improve the health and productivity of livestock animals, companion animals and fish.
EMERGENT BIOSOLUTIONS has reported second quarter of FY2023 financial results, showing an increase in total revenue of 39.2% year-over-year to USD 337.9 million. However, net income decreased from -56.4 million in the same period last year to -261.3 million. This decline in profit may indicate a bad investment opportunity for EMERGENT BIOSOLUTIONS, with investors needing to carefully consider the company’s future outlook and potential strategies before investing.